Hikma shares up 7%

Listen to this article


Hikma Pharmaceuticals is topping the FTSE All Share this morning after the company reported better than expected results for 2016.

The generic drug specialist earlier said that a fall in operating profits last year was not as bad as expected, while revenues were a touch better than expectations.

Hikma also slightly raised its dividend for last year and predicted revenue growth of 10 per cent in 2017.

Copyright The Financial Times Limited 2017. All rights reserved. You may share using our article tools. Please don't copy articles from FT.com and redistribute by email or post to the web.